Published in J Control Release on May 06, 2014
Bioactive cell-like hybrids coassembled from (glyco)dendrimersomes with bacterial membranes. Proc Natl Acad Sci U S A (2016) 0.80
Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. PLoS One (2015) 0.75
Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer. Nanomaterials (Basel) (2016) 0.75
Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic. BMC Res Notes (2016) 0.75
Building Synthetic Sterols Computationally - Unlocking the Secrets of Evolution? Front Bioeng Biotechnol (2015) 0.75
Sulfated quaternary amine lipids: a new class of inverse charge zwitterlipids. Chem Commun (Camb) (2014) 0.75
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
A comprehensive classification system for lipids. J Lipid Res (2005) 6.52
Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev (2012) 4.30
Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta (1991) 4.16
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine (2006) 4.08
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev (1999) 4.02
Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release (2006) 3.85
Delivery materials for siRNA therapeutics. Nat Mater (2013) 3.70
High-sensitivity scanning calorimetric study of mixtures of cholesterol with dimyristoyl- and dipalmitoylphosphatidylcholines. Biochemistry (1978) 3.60
Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release (2012) 3.41
Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater (2011) 3.40
Sterically stabilized liposomes. Biochim Biophys Acta (1992) 3.10
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A (1988) 2.74
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem (1977) 2.65
Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science (2013) 2.42
A self-assembled monolayer for the binding and study of histidine-tagged proteins by surface plasmon resonance. Anal Chem (1996) 2.20
The effect of sterol structure on the permeability of lipomes to glucose, glycerol and Rb + . Biochim Biophys Acta (1972) 2.12
Nanomedicine(s) under the microscope. Mol Pharm (2011) 2.09
Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine (2011) 2.09
Mechanisms and consequences of cellular cholesterol exchange and transfer. Biochim Biophys Acta (1987) 2.08
Role of membrane organization and membrane domains in endocytic lipid trafficking. Traffic (2000) 2.02
Differential scanning calorimetric study of the effect of cholesterol on the thermotropic phase behavior of a homologous series of linear saturated phosphatidylcholines. Biochemistry (1993) 1.96
Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta (1991) 1.75
Engineering nano- and microparticles to tune immunity. Adv Mater (2012) 1.75
A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol (2013) 1.70
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci (2008) 1.67
Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev (2012) 1.66
Permeability properties of phospholipid membranes: effect of cholesterol and temperature. Biochim Biophys Acta (1972) 1.56
Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther (2001) 1.55
Lateral hapten mobility and immunochemistry of model membranes. Proc Natl Acad Sci U S A (1976) 1.54
Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res (1999) 1.54
Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta (1986) 1.52
Fast flip-flop of cholesterol and fatty acids in membranes: implications for membrane transport proteins. Curr Opin Lipidol (2003) 1.48
Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim Biophys Acta (2005) 1.36
PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release (2007) 1.34
Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J Biol Chem (1982) 1.32
Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther (2000) 1.32
Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A. J Immunol (1979) 1.30
Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol (2002) 1.29
Phospholipid/cholesterol model membranes: formation of cholesterol crystallites. Biochim Biophys Acta (2003) 1.28
Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci (2004) 1.26
Immune response of a liposomal model membrane. Proc Natl Acad Sci U S A (1968) 1.24
Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther (2004) 1.23
Molecular mechanisms of calcium-induced membrane fusion. J Bioenerg Biomembr (1990) 1.22
Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine (2012) 1.21
New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug Chem (1995) 1.20
Facile synthesis of multivalent nitrilotriacetic acid (NTA) and NTA conjugates for analytical and drug delivery applications. Bioconjug Chem (2006) 1.19
Antibody formation in response to liposomal model membranes sensitized with N-substituted phosphatidylethanolamine derivatives. Biochemistry (1974) 1.19
Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s. J Control Release (2007) 1.17
Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim Biophys Acta (1994) 1.17
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res (2001) 1.17
The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release (2013) 1.16
Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs (1990) 1.14
Porphyrin shell microbubbles with intrinsic ultrasound and photoacoustic properties. J Am Chem Soc (2012) 1.14
The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta (1992) 1.13
Self-adjuvanting lipopeptide vaccines. Curr Med Chem (2008) 1.10
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Release (2006) 1.09
Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release (2010) 1.08
Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev (2009) 1.07
Rates of spontaneous exchange of synthetic radiolabeled sterols between lipid vesicles. Biochemistry (1992) 1.06
Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. J Pharm Sci (1996) 1.05
SuperHapten: a comprehensive database for small immunogenic compounds. Nucleic Acids Res (2006) 1.05
Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther (2003) 1.05
Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release (2001) 1.04
Medicinal chemistry of siRNA delivery. J Med Chem (2010) 1.04
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer (2001) 1.02
Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev (2009) 1.02
Immunological risk of injectable drug delivery systems. Pharm Res (2009) 1.02
Tris-nitrilotriacetic acids of subnanomolar affinity toward hexahistidine tagged molecules. Bioconjug Chem (2009) 1.02
Recent developments in oligonucleotide conjugation. Chem Soc Rev (2010) 1.01
Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J Am Chem Soc (2008) 0.99
T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm (2010) 0.99
Biomimetic polymers in pharmaceutical and biomedical sciences. Eur J Pharm Biopharm (2004) 0.98
Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res (1999) 0.98
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol (2010) 0.97
Prodrug-based intracellular delivery of anticancer agents. Adv Drug Deliv Rev (2011) 0.97
Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids. Org Biomol Chem (2008) 0.96
Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting. Langmuir (2008) 0.95
A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol (2006) 0.95
Exotic aqueous behavior of synthetic lipids: formation of vesicular nanotubes. Chem Phys Lipids (2005) 0.95
The use of PVP as a polymeric carrier to improve the plasma half-life of drugs. Biomaterials (2004) 0.94
Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. ACS Nano (2011) 0.94
A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem (2003) 0.94
Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg Med Chem Lett (2006) 0.94
Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice. Clin Vaccine Immunol (2010) 0.94
Lipid membrane adhesion and fusion driven by designed, minimally multivalent hydrogen-bonding lipids. J Am Chem Soc (2009) 0.93
DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs (2007) 0.93
Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta (2002) 0.92
Immune response mediated by liposome-associated protein antigens. III. Immunogenicity of bovine serum albumin covalently coupled to vesicle surface. Immunology (1983) 0.92
Cationic nucleoside lipids for gene delivery. Bioconjug Chem (2006) 0.92
The release and detection of endotoxin from liposomes. Anal Biochem (1997) 0.90
The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells. Biochim Biophys Acta (2005) 0.90
Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol (1994) 0.90
Self-assembled porphyrin nanodiscs with structure-dependent activation for phototherapy and photodiagnostic applications. ACS Nano (2013) 0.90
Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy. J Control Release (2011) 0.89
Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin. Faraday Discuss (2013) 0.89
Inverse-phosphocholine lipids: a remix of a common phospholipid. J Am Chem Soc (2012) 0.89
Zwitterionic sulfobetaine lipids that form vesicles with salt-dependent thermotropic properties. Chem Commun (Camb) (2011) 0.88
Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan. J Control Release (2014) 0.78
Macrophage-based cell therapies: The long and winding road. J Control Release (2016) 0.78